Top Mesothelioma Centers in Florida

The best cancer centers for mesothelioma in Florida include research hubs, sites offering the latest advancements and NCI-designated comprehensive cancer centers: Moffitt Cancer Center in Tampa and Sylvester Comprehensive Cancer Center in Miami. NCI designation means both centers meet rigorous federal standards for cancer research, multidisciplinary care and access to cutting-edge clinical trials, giving patients access to the same level of care available at leading centers nationwide.

Patients across the state also have access to specialized care at AdventHealth and Orlando Health in Orlando, Baptist Health and Sylvester in Miami, Baptist MD Anderson and Mayo Clinic in Jacksonville, Cleveland Clinic Florida in Weston, Jupiter Medical Center, Tampa General and UF Health in Gainesville. Many top cancer centers in Florida house teams of specialists dedicated to mesothelioma treatment who collaborate on every patient case.

Locations of Florida’s Cancer Centers

Mesothelioma treatment in Florida is available in several major cities, including Jacksonville, Miami, Orlando and Tampa, where leading cancer centers offer specialized care for both pleural and peritoneal mesothelioma. Patients in North Florida can access care at Mayo Clinic and Baptist MD Anderson in Jacksonville or UF Health in Gainesville. The state’s 2 NCI-designated comprehensive cancer centers, Moffitt Cancer Center and Sylvester Comprehensive Cancer Center, are located in central Florida and Southeast Florida respectively.

All Centers (9)

Top Doctors in Florida

The best mesothelioma doctors in Florida are specialists who focus specifically on pleural or peritoneal mesothelioma, lead or participate in clinical research and work within multidisciplinary teams at leading cancer centers. Florida’s specialists include thoracic surgeons like Dr. Jacques Fontaine at Moffitt and Dr. Nestor Villamizar at Sylvester, medical oncologists like Dr. Mark Socinski at AdventHealth Orlando, and GI oncologists like Dr. Iman Imanirad at Moffitt and Dr. Sarbajit Mukherjee at Baptist Miami who specialize in peritoneal mesothelioma care.

Mesothelioma specialists in Florida practice at more than a dozen centers, from Mayo Clinic and Baptist MD Anderson in Jacksonville to Jupiter Medical Center and Baptist Health in Miami. Many hold leadership roles in clinical research and participate in trials that give patients access to treatments not yet widely available.

Dr. Jacques Fontaine

Jacques Fontaine

Pleural Specialist | Thoracic Surgery

Expertise:
Pleural Mesothelioma Lung Cancer Thoracic Diseases Minimally Invasive Surgery Pleurectomy and Decortication Surgery
Moffitt Cancer Center • Tampa, Florida
View Profile
Expertise:
Pleural Mesothelioma Lung Cancer Thoracic Diseases Minimally Invasive Surgery Pleurectomy and Decortication Surgery
Moffitt Cancer Center
Tampa, Florida
View Profile

Dr. Jacques Fontaine is the Director of the Mesothelioma Research and Treatment Center at Moffitt Cancer Center in Tampa, Florida. He specializes in minimally invasive thoracic surgery including robotic surgery. Fontaine became a pleural mesothelioma specialist while studying under Dr. Sugarbaker at the International Mesothelioma Program at Brigham & Women’s Hospital.

Read Bio
Dr. Marcelo DaSilva

Marcelo DaSilva

Pleural Specialist | Thoracic Surgery

Expertise:
Pleural Mesothelioma Robotic Surgery Heated Chemotherapy Chest Reconstruction
AdventHealth Orlando • Orlando, Florida
View Profile
Expertise:
Pleural Mesothelioma Robotic Surgery Heated Chemotherapy Chest Reconstruction
AdventHealth Orlando
Orlando, Florida
View Profile

Dr. Marcelo DaSilva is medical director of thoracic surgery at the AdventHealth Cancer Institute, where he has built the Mesothelioma International Treatment Program.

Read Bio
Dr. Nestor Villamizar

Nestor Villamizar

Pleural Specialist | Cardiothoracic Surgery

Expertise:
Pleural Mesothelioma Lung Cancer Pleurectomy and Decortication Surgery Minimally Invasive Robotic Surgery
Sylvester Cancer Center at University of Miami • Miami, Florida
View Profile
Expertise:
Pleural Mesothelioma Lung Cancer Pleurectomy and Decortication Surgery Minimally Invasive Robotic Surgery
Sylvester Cancer Center at University of Miami
Miami, Florida
View Profile

Thoracic surgeon Dr. Nestor Villamizar has raised the level of treatment for pleural mesothelioma patients at the Sylvester Cancer Center and the University of Miami Health System. He came to Miami from Brigham and Women’s Hospital in Boston, where he worked alongside mesothelioma treatment pioneer Dr. David Sugarbaker.

Read Bio

Find a Specialist in Florida

Searching…

Clinical Trials in Florida

Your mesothelioma doctor or a Patient Advocate can help you explore which clinical trials you may be eligible for, such as trials currently enrolling at Mayo Clinic in Jacksonville or Sylvester Comprehensive Cancer Center in Miami. Florida’s leading centers, including Moffitt Cancer Center in Tampa and Sylvester, are active hubs for mesothelioma clinical trials, giving patients access to emerging treatments not yet widely available.

NCT05245500

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

Locations

  • Arizona (1)

    • Mayo Clinic — Phoenix

  • Colorado (2)

    • Sarah Cannon Research Institute (SCRI) – HealthONE Location — Denver
    • Rocky Mountain Cancer Centers, LLP – Oncology — Lone Tree

  • Florida (2)

    • Mayo Clinic — Jacksonville
    • Sarah Cannon Research Institute at Florida Cancer Specialists — Orlando

  • Massachusetts (1)

    • Dana-Farber Cancer Institute — Brookline

  • Michigan (1)

    • Cancer and Hematology Centers of Western Michigan — Norton Shores

  • Minnesota (1)

    • Mayo Clinic — Rochester

  • New Jersey (1)

    • Rutgers Cancer Institute of New Jersey — New Brunswick

  • New York (3)

    • David H Koch, Memorial Sloan Kettering Cancer Center — New York
    • New york cancer and blood specialists – Oncology — Port Jefferson Station
    • New york cancer and blood specialists – Oncology — Port Jefferson Station

  • North Carolina (2)

    • University of North Carolina – Gastroenterology and Hepatology — Chapel Hill
    • University of North Carolina — Chapel Hill

  • Tennessee (1)

    • Vanderbilt – Ingram Cancer Center — Nashville

  • Texas (5)

    • Ut Southwestern — Dallas
    • Texas Oncology – DFW — Fort Worth
    • MDACC — Houston
    • South Texas Accelerated Research Therapeutics — San Antonio
    • Texas Oncology, P.A. – Oncology — Tyler

  • Virginia (1)

    • Virginia Cancer Specialists, PC — Fairfax

NCT02012699

Integrated Cancer Repository for Cancer Research

The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.

Locations

  • Colorado (1)

    • Advent Health — Greenwood Village

  • Connecticut (1)

    • Hartford HealthCare Cancer Institute at Manchester Medical Hospital — Manchester

  • Florida (5)

    • Florida Hospital Memorial Medical Center — Daytona Beach
    • Florida Hospital DeLand — DeLand
    • Florida Hospital FISH — Orange City
    • Florida Hospital Flagler — Palm Coast
    • Tallahassee Memorial Hospital — Tallahassee

  • Illinois (2)

    • Rush-Copley Cancer Care Center — Aurora
    • Rush-Copley Healthcare Center — Yorkville

  • Indiana (1)

    • Parkview Research Center — Fort Wayne

  • Iowa (2)

    • Methodist Jennie Edmundson Hospital — Council Bluffs
    • Covenant Medical Center, Inc — Waterloo

  • Kansas (1)

    • Saint Luke's Cancer Instititute – South — Overland Park

  • Maryland (2)

    • Northwest Hospital — Randallstown
    • William E. Kahlert Regional Cancer Center — Westminster

  • Massachusetts (1)

    • Holyoke Medical Center — Holyoke

  • Minnesota (5)

    • Riverwood Healthcare Center — Aitkin
    • Essentia Health-St. Joseph's Medical Center — Brainerd
    • Essentia Health – Duluth Clinic — Duluth
    • St. Luke's Hospital of Duluth — Duluth
    • Lake Region Healthcare — Fergus Falls

  • Missouri (6)

    • Saint Luke's Cancer Institute, East — Kansas City
    • Saint Luke's Cancer Institute — Kansas City
    • Saint Luke's Cancer Institute, Kansas City North — Kansas City
    • Saint Luke's Cancer Institute, Liberty — Liberty
    • North Kansas City Hospital — North Kansas City
    • Heartland Regional Medical Center dba Mosaic Life Care — Saint Joseph

  • Montana (1)

    • Bozeman Health Deaconess Hospital — Bozeman

  • Nebraska (6)

    • Mary Lanning Healthcare, Morrison Cancer Center — Hastings
    • Faith Regional Health Services, Carson Cancer Center — Norfolk
    • Great Plains Regional Medical Center — North Platte
    • Methodist Estabrook Cancer Center — Omaha
    • Nebraska Methodist Health System — Omaha
    • University of Nebraska Medical Center — Omaha

  • New York (2)

    • C.R. Wood Cancer Center, Glens Falls Hospital — Glens Falls
    • Faxton St. Luke's Healthcare, Mohawk Valley — Utica

  • North Carolina (1)

    • Cape Fear Valley Health System — Fayetteville

  • North Dakota (2)

    • Essentia Health — Fargo
    • Trinity Hospital Cancer Care Center — Minot

  • Ohio (2)

    • Aultman Alliance Community Hospital — Alliance
    • Aultman Hospital — Canton

  • Wisconsin (1)

    • Bellin Memorial Hospital — Green Bay

NCT06444815

A Study of VET3-TGI in Patients With Solid Tumors

VET3-TGI is an oncolytic immunotherapy designed to treat advanced cancers. VET3-TGI has not been given to human patients yet, and the current study is designed to find a safe and effective dose of VET3-TGI when administered by direct injection into tumor(s) (called an intratumoral injection) or when given intravenously (into the vein) both alone and in combination with atezolizumab in patients with solid tumors (STEALTH-001).

Locations

  • California (2)

    • USC/Norris Comprehensive Cancer Center — Los Angeles
    • UC Irvine Health — Orange

  • Florida (1)

    • University of Miami — Miami

  • Indiana (1)

    • Community Health Network — Indianapolis

  • Pennsylvania (1)

    • UPMC- Hillman Cancer Center — Pittsburgh

  • Texas (2)

    • Mary Crowley Cancer Research — Dallas
    • University of Texas MD Anderson Cancer Center — Houston

NCT05086692

A Beta-only IL-2 ImmunoTherapY Study

This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a checkpoint inhibitor in patients with advanced solid tumors.

Locations

  • California (2)

    • Sharp Memorial Hospital — San Diego
    • Providence Saint John's Health Center — Santa Monica

  • Florida (1)

    • Boca Raton Regional Hospital — Boca Raton

  • Georgia (1)

    • Emory – Winship Cancer Institute — Atlanta

  • Michigan (1)

    • Karmanos Cancer Institute — Detroit

NCT06051695

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesothelin (MSLN) and have lost HLA-A\*02 expression. The main questions this study aims to answer are: Phase 1: What is the recommended dose that is safe for patients Phase 2: Does the recommended dose kill solid tumor cells and protect the patient's healthy cells Participants will be required to perform study procedures and assessments, and will also receive the following study treatments: Enrollment and Apheresis in BASECAMP-1 (NCT04981119) Preconditioning Lymphodepletion (PCLD) Regimen Tmod CAR T cells at the assigned dose

Locations

  • Arizona (1)

    • Banner Health — Gilbert

  • California (3)

    • UCSD Moores Cancer Center — La Jolla
    • UCLA Medical Center — Los Angeles
    • Stanford University — Stanford

  • Florida (2)

    • Mayo Clinic — Jacksonville
    • Moffitt Cancer Center — Tampa

  • Minnesota (1)

    • Mayo Clinic Rochester — Rochester

  • Missouri (1)

    • Washington University — St Louis

  • New York (1)

    • NYU Langone Medical Center — New York

  • Ohio (1)

    • The Ohio State University Comprehensive Cancer Center — Columbus

  • Tennessee (1)

    • Vanderbilt University Medical Center — Nashville

  • Washington (1)

    • Fred Hutchinson Cancer Center — Seattle

NCT05579366

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

Locations

  • Arizona (2)

    • USOR HonorHealth — Phoenix
    • USOR Arizona Oncology Associates — Tucson

  • California (4)

    • University of California Los Angeles Medical Center — Los Angeles
    • University of California, San Diego; Moores Cancer Center — San Diego
    • USOR Sansum Clinic — Santa Barbara
    • Providence Medical Foundation — Santa Rosa

  • Florida (3)

    • USOR Florida Cancer Specialists South — Fort Myers
    • USOR Florida Cancer Specialists North — St. Petersburg
    • USOR Florida Cancer Specialists East — West Palm Beach

  • Georgia (1)

    • Augusta University Georgia Cancer Center — Augusta

  • Kansas (1)

    • University of Kansas Medical Center (KUMC) — Westwood

  • Maryland (1)

    • USOR Maryland Oncology Hematology — Rockville

  • Massachusetts (2)

    • Massachusetts General Hospital — Boston
    • Dana Farber Cancer Institute — Boston

  • Michigan (2)

    • Karmanos Cancer Institute — Detroit
    • START Midwest — Grand Rapids

  • Minnesota (1)

    • USOR Minnesota Oncology Hematology — Maplewood

  • New Jersey (1)

    • MD Anderson Cancer Center at Cooper- Two Cooper Plaza — Camden

  • Ohio (1)

    • Ohio State University Comprehensive Cancer Center (OSUCCC)- The James Cancer Hospital and Solove Research Institute — Columbus

  • Oklahoma (1)

    • University of Oklahoma – Health Sciences Center — Oklahoma City

  • Oregon (2)

    • USOR Oncology Associates of Oregon, P.C. — Eugene
    • Compass Oncology – Rose Quarter — Portland

  • Pennsylvania (2)

    • USOR Alliance Cancer Specialist — Doylestown
    • Allegheny Health Network — Pittsburgh

  • Rhode Island (1)

    • Women and Infants Hospital of Rhode Island — Providence

  • Tennessee (2)

    • Sarah Cannon Research Institute at Tennessee Oncology — Nashville
    • Tennessee Oncology — Nashville

  • Texas (6)

    • USOR Texas Oncology — Abilene
    • Texas Oncology – Central / South Texas — Austin
    • Mary Crowley Cancer Research — Dallas
    • USOR Texas Oncology — Fort Worth
    • Texas Oncology – Northeast TX — Tyler
    • USOR Texas Oncology Gulf Coast — Woodland

  • Utah (1)

    • START Mountain Region — West Valley City

  • Virginia (2)

    • USOR Virginia Cancer Specialists — Fairfax
    • USOR Virginia Oncology Associates — Norfolk

  • Washington (1)

    • Swedish Cancer Institute — Seattle

NCT04981119

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

Objective: To collect information on how often a solid tumor cancer might lose the Human Leukocyte Antigen (HLA) by next generation sequencing and perform apheresis to collect and store an eligible participant's own T cells for future use to make CAR T-Cell therapy for their disease treatment. Design: This is a non-interventional, observational study to evaluate participants with solid tumors with a high risk of relapse for incurable disease. No interventional therapy will be administered on this study. Some of the information regarding the participant's tumor analysis may be beneficial to management of their disease. Participants that meet all criteria may be enrolled and leukapheresed (blood cells collected). The participant's cells will be processed and stored for potential manufacture of CAR T-cell therapy upon relapse of their cancer.

Locations

  • Arizona (2)

    • Banner Health — Gilbert
    • Mayo Clinic Hospital — Phoenix

  • California (3)

    • University of California San Diego — La Jolla
    • Stanford University — Palo Alto
    • UCLA Medical Center — Santa Monica

  • Florida (2)

    • Mayo Clinic Jacksonville — Jacksonville
    • Moffitt Cancer Center — Tampa

  • Minnesota (1)

    • Mayo Clinic Rochester — Rochester

  • Missouri (1)

    • Washington University — St Louis

  • New York (1)

    • NYU Langone Medical Center — New York

  • Ohio (1)

    • The Ohio State University Comprehensive Cancer Center — Columbus

  • Tennessee (1)

    • Vanderbilt University Medical Center — Nashville

  • Washington (1)

    • Fred Hutchinson Cancer Center — Seattle

NCT03556228

VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma

This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non responsive to available therapies and for which no standard or available curative therapy exists

Locations

  • California (1)

    • Providence Medical Foundation (site 209) — Santa Rosa

  • Connecticut (1)

    • Hartford Hospital (site 210) — Hartford

  • District of Columbia (1)

    • The George Washington University Cancer Center (site 212) — Washington D.C.

  • Florida (2)

    • Holy Cross Hospital (site 213) — Fort Lauderdale
    • Memorial Cancer Institute at Memorial Healthcare Systems (site 132) — Pembroke Pines

  • New Jersey (3)

    • Englewood Hospital and Medical Center (site 202) — Englewood
    • Summit Medical Group (site 205) — Florham Park
    • Atlantic Health System, Morristown Medical Center (site 124) — Morristown

  • New Mexico (1)

    • Presbyterian Kaseman Hospital (site 208) — Albuquerque

  • New York (1)

    • Weill Cornell Medicine, Cornell University (site 126) — New York

  • Ohio (1)

    • Taylor Cancer Research Center (site 204) — Maumee

  • Pennsylvania (1)

    • Cancer Care Associates of York (site 206) — York

  • Texas (1)

    • The University of Texas MD Anderson Cancer Center (site 127) — Houston

  • Utah (1)

    • Utah Cancer Specialists (site 203) — Salt Lake City

NCT05568680

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma.

Locations

  • Florida (1)

    • Moffitt Cancer Center — Tampa

  • Kansas (1)

    • University of Kansas Cancer Center — Westwood

  • Pennsylvania (1)

    • University of Pennsylvania — Philadelphia

  • Texas (1)

    • MD Anderson Cancer Center — Houston

  • Wisconsin (1)

    • University of Wisconsin Carbone Cancer Center — Madison

NCT05732831

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.

Locations

  • California (1)

    • Stanford University — Palo Alto

  • Colorado (1)

    • Grand Valley Oncology — Grand Junction

  • Florida (1)

    • Sylvester Comprehensive Cancer Center — Miami

  • Illinois (3)

    • University Chicago Medicine — Chicago
    • Carle Cancer Center — Urbana
    • Midwestern Regional Medical Center, City of Hope Chicago — Zion

  • Massachusetts (2)

    • Massachusetts General Hospital — Boston
    • Dana Farber Cancer Institute — Boston

  • Michigan (1)

    • Henry Ford Cancer Center — Detroit

  • New York (1)

    • New York University Langone Health — New York

  • Tennessee (1)

    • Sarah Cannon Tennessee Oncology — Nashville

  • Texas (1)

    • The University of Texas MD Anderson Cancer Center — Houston

  • Utah (1)

    • Huntsman Cancer Institute, University of Utah — Salt Lake City

  • Virginia (1)

    • Next Oncology Virginia — Fairfax

NCT06710756

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Phase I/IIa image-guided, alpha-particle therapy study of \[203Pb\]Pb-PSV359 and \[212Pb\]Pb-PSV359 in patients with solid tumors that are known to be Fibroblast Activation Protein (FAP)-positive.

Locations

  • Florida (2)

    • University of Miami — Miami
    • Biogenix — Miami

  • Kentucky (1)

    • University of Kentucky — Lexington

  • Missouri (1)

    • Saint Louis University — St Louis

  • Nebraska (1)

    • Nebraska Cancer Specialists — Omaha

  • Ohio (1)

    • Ohio State University — Columbus

  • Pennsylvania (1)

    • University of Pittsburgh Medical Center — Pittsburgh

  • Texas (1)

    • MD Anderson Cancer Center — Houston

NCT07277413

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.

Locations

  • Florida (1)

    • Sarah Cannon Research Institute at Florida Cancer Specialists — Orlando

  • Nebraska (1)

    • Nebraska Cancer Specialists — Omaha

  • New York (1)

    • Columbia University Irving Medical Center — New York

  • Pennsylvania (1)

    • Sidney Kimmel Comprehensive Cancer Center Thomas Jefferson University — Philadelphia

  • Tennessee (1)

    • Sarah Cannon Research Institute — Nashville

  • Texas (4)

    • START Dallas Fort Worth — Fort Worth
    • MD Anderson — Houston
    • NEXT Oncology Houston — Houston
    • NEXT Oncology Dallas — Irving

  • Utah (1)

    • START Mountain Region, LLC — West Valley City

  • Virginia (1)

    • NEXT Oncology Virginia — Fairfax

  • Washington (1)

    • Swedish Cancer Institute — Seattle

NCT05873686

A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers

This is a multi-center, first-in-human, open label, dose escalation (Part A) and expansion (Part B) Phase 1 study in subjects with advanced solid tumors and in subjects with solid tumors with selected genetic alterations that are either direct (YES1 amplification) or dependent (Hippo Pathway alterations) targets of NXP900.

Locations

  • Arizona (1)

    • Mayo Clinic — Phoenix

  • Colorado (1)

    • Sarah Cannon Research Institute at HealthONE — Denver

  • Florida (1)

    • Mayo Clinic — Jacksonville

  • Illinois (1)

    • University of Chicago — Chicago

  • Minnesota (1)

    • Mayo Clinic Rochester — Rochester

  • Oregon (1)

    • Oregon Health and Science University — Portland

  • Texas (3)

    • The University of Texas MD Anderson Cancer Center — Houston
    • NEXT Oncology Houston — Houston
    • NEXT Oncology Dallas — Irving

  • Virginia (1)

    • NEXT Oncology Virginia — Fairfax

Financial Support for Treatment in Florida

Mesothelioma patients can access financial assistance through organizations offering help with medical bills, travel expenses and basic needs, including Florida-specific programs like Florida Cancer Connect and the Mission Blue Foundation. These resources are designed to ease the financial burden that often comes with a mesothelioma diagnosis.

Financial Resources for Florida Mesothelioma Patients

  • Cancer Alliance of Help & Hope: This Palm Beach County nonprofit helps qualified cancer patients cover non-medical bills and basic needs like food and clothing. The organization also connects patients with support information and community resources.
  • Florida Cancer Connect: Florida Department of Health created this state resource hub in partnership with the Florida Agency for Health Care Administration. It helps cancer patients and caregivers find local healthcare providers, navigate insurance coverage and access cancer research and prevention programs.
  • Mission Blue Foundation: This Central Florida nonprofit provides direct support to cancer patients in need, including medical assistance, transportation to treatments and food. The foundation serves patients throughout the Orange City area and surrounding communities.

Patients can also speak with a Patient Advocate to learn about additional financial resources. Veterans diagnosed with mesothelioma may be eligible for VA benefits, including disability compensation and survivor benefits. Our Veterans Department can help people file claims and navigate what can be a complex approval process.

Cancer Resources in Florida

Mesothelioma patients in Florida can access a range of support services including counseling, cancer rehabilitation and meal assistance through organizations like Gilda’s Club South Florida and the Cancer Support Community in Orlando. These resources serve patients and caregivers at any stage of a mesothelioma diagnosis.

Cancer Support Resources in Florida

  • American Cancer Society: The organization offers programs and services to help people with cancer and their loved ones manage treatment and recovery. Resources include free wigs, hats, treatment information and help finding emotional support networks and financial assistance.
  • Cancer Support Community: A service of Orlando Health, the Cancer Support Community at UF Health Cancer Center welcomes any person with cancer, as well as survivors and caregivers. The community uses integrative medical techniques to manage symptoms, relieve stress and improve mental health. Members have access to nutritionists, counselors, pain specialists and palliative treatment consultations.
  • Gilda’s Club South Florida: Available in Fort Lauderdale and nearby communities, Gilda’s Club offers support groups, healthy living workshops, social gatherings and financial support for anyone facing a cancer diagnosis. Professionals lead a range of seminars and the organization builds a strong community presence throughout South Florida.

Florida patients can also call 211 to connect with local support services in their county. Transportation, food assistance and home care resources are all available through this free service.

What Survivors Say About Their Mesothelioma Treatment in Florida

Mesothelioma patients treated in Florida have shared their experiences with us, from surgery and chemotherapy at AdventHealth Cancer Institute in Orlando to clinical trials and multidisciplinary treatment at Moffitt Cancer Center in Tampa. Their stories reflect the range of care Florida’s leading cancer centers offer every day.

“I believe with my heart that those who survive are warriors,” Goodson said. “I often joke with my friends that mesothelioma whispered in my ear, ‘You can’t handle me.’ And I told mesothelioma, no, you can’t handle me.”

Judy Goodson , Peritoneal Mesothelioma Survivor

“I’m enjoying life now. Doctors tell me I’m doing great and looking good,” he said. “They also tell me there’s a 75% chance of it coming back, but if I get to five years, I’ve beaten it. I’ve got things to do.”

Charles and Sharon Wood
Charles Wood , Peritoneal Mesothelioma Survivor

“It’s a hard time and a lot of tough decisions, and it’s nice to have well-informed people who have a lot of information to share with you,” she said. “It really is. It’s a good thing.”

Carla Fasolo
Carla Fasolo , Peritoneal Mesothelioma Survivor

Their stories offer hope to others experiencing mesothelioma, whether as a patient or a loved one. Read more of their inspirational stories in our Wall of Hope.